

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Teduglutide for treating short bowel syndrome [ID3937]

#### Final Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Takeda (teduglutide)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>Black Health Agency</li> <li>Bladder and Bowel Community</li> <li>Bladder and Bowel UK</li> <li>Bowel Cancer Information</li> <li>Bowel Cancer UK</li> <li>Chrohn's in Childhood Research Association (CICRA)</li> <li>Colostomy UK</li> <li>Crohn's and Colitis UK</li> <li>GUTSUK</li> <li>IA: Ileostomy and Internal Pouch</li> <li>Muslim Council of Britain</li> <li>Patients On Intravenous &amp; Nasogastric Nutrition Therapy (PINNT)</li> <li>Pelican Cancer Foundation</li> <li>Short Bowel Survivors &amp; Friends</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>The IBS Network</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>Association for Continence Advice</li> <li>Association of Coloproctology of Great Britain and Ireland</li> <li>British Society of Gastroenterology</li> <li>British Society of Paediatric Gastroenterology, hepatology &amp; Nutrition</li> <li>British Geriatrics Society</li> <li>Lennard Jones Intestinal Failure Unit, St Marks Hospital</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Alliance</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Scottish Society of Gastroenterology</li> <li>Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator company(ies)</u></p> <ul style="list-style-type: none"> <li>Accord Healthcare (cimetidine, omeprazole, ranitidine)</li> <li>Allergan (lansoprazole, omeprazole)</li> <li>Alliance pharmaceuticals (ranitidine)</li> <li>AstraZeneca (omeprazole)</li> <li>Aurobindo Pharma (ranitidine)</li> <li>Bristol Laboratories (ranitidine)</li> <li>Chugai Pharma (sucralfate)</li> <li>Concordia International (ranitidine)</li> <li>Dexcel Pharma (omeprazole)</li> <li>Dr Reddy's Laboratories (omeprazole)</li> <li>GlaxoSmithKline (ranitidine)</li> <li>Janssen-Cilag (loperamide)</li> </ul>

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• Primary Care Society for Gastroenterology</li> <li>• UK Continence Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Cumbria CCG</li> <li>• NHS Redditch and Bromsgrove CCG</li> <li>• Great Ormond Street Hospital (GOSH)</li> <li>• Birmingham Women’s and Children’s NHS Foundation Trust</li> <li>• Intestinal Failure Unit, Salford Royal NHS Foundation Trust</li> <li>• NHS England</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Lupin (lansoprazole)</li> <li>• McNeil Products (loperamide)</li> <li>• Omega Pharma (ranitidine)</li> <li>• Pfizer (lansoprazole)</li> <li>• Reckitt Benckiser Healthcare (loperamide, ranitidine)</li> <li>• Rosemont (cimetidine, ranitidine)</li> <li>• Sandoz (omeprazole)</li> <li>• The Boots Company (loperamide, omeprazole, ranitidine)</li> <li>• Wockhardt UK (loperamide)</li> <li>• Zentiva (lansoprazole, loperamide, omeprazole)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group</li> <li>• CORE (formally Digestive Disorders Foundation)</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

## **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the recommendations.

All non-company/sponsor consultees are invited to make an evidence submission or submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the recommendations.

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: companies that market technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company/sponsor commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.